Sec Form 3 Filing - Bjorkquist Jeanette M @ ASSEMBLY BIOSCIENCES, INC. - 2022-09-09

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bjorkquist Jeanette M 2. Issuer Name and Ticker or Trading Symbol ASSEMBLY BIOSCIENCES, INC. [ ASMB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Principal Accounting Officer (Last) (First) (Middle) C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 09/09/2022 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 15,830( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 15.34 ( 2 ) 05/01/2029 Common Stock 7,000 D Stock Options (right to buy) $ 14.45 ( 3 ) 03/29/2030 Common Stock 3,100 D Stock Options (right to buy) $ 4.33 ( 4 ) 03/29/2031 Common Stock 3,700 D Stock Options (right to buy) $ 2.3 ( 5 ) 03/29/2032 Common Stock 10,000 D Stock Options (right to buy) $ 2.01 ( 6 ) 08/01/2032 Common Stock 32,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bjorkquist Jeanette M C/O ASSEMBLY BIOSCIENCES, INC. 331 OYSTER POINT BLVD, FOURTH FLOOR SOUTH SAN FRANCISCO, CA94080 Principal Accounting Officer Signatures /s/ John O. Gunderson, as Attorney-in-Fact 09/13/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Holdings include grants of restricted stock units (RSUs) vesting, in each case assuming continuous service on each vesting date, as follows: (a) 2,250 RSUs vesting on July 22, 2023; (b) 775 RSUs vesting in approximately equal installments on March 29, 2023 and March 29, 2024; (c) 1,388 RSUs vesting in approximately equal installments on March 29, 2023, March 29, 2024 and March 29, 2025; and (d) 5,000 RSUs vesting in equal installments on March 29, 2023, March 29, 2024, March 29, 2025 and March 29, 2026. ( 2 )Grant of stock options. Options to purchase 5,833 shares of common stock have vested, and, assuming continuous service on each vesting date, the remaining stock options vest in eight approximately equal monthly installments, with the options becoming fully vested on May 1, 2023. ( 3 )Grant of stock options. Options to purchase 1,872 shares of common stock have vested, and, assuming continuous service on each vesting date, the remaining stock options vest in 19 approximately equal monthly installments, with the options becoming fully vested on March 29, 2024. ( 4 )Grant of stock options. Options to purchase 1,310 shares of common stock have vested, and, assuming continuous service on each vesting date, the remaining stock options vest in 31 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025. ( 5 )Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026. ( 6 )Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, August 1, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on August 1, 2026.

Remarks: Exhibit List: Exhibit 24.1 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.